Nature Medicine, Published online: 17 February 2025; doi:10.1038/s41591-025-03513-0
In an extended follow-up of a phase 1 trial evaluating a first-generation GD2-directed CAR-T cell therapy in patients with neuroblastoma, one patient has had a sustained clinical response for over 18 years without requiring any additional therapy, with translational data from long-term survivors providing broader insights into potential determinants of CAR-T cell response.
